Back to Browse Journals » Open Access Emergency Medicine » Volume 2

Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole

Authors Bruno Mégarbane

Published Date August 2010 Volume 2010:2 Pages 67—75

DOI http://dx.doi.org/10.2147/OAEM.S5346

Published 26 August 2010

Bruno Mégarbane
Réanimation Médicale et Toxicologique, Hôpital Lariboisière and Université Paris-Diderot, Paris, France
Abstract: Ethylene glycol (EG) and methanol are responsible for life-threatening poisonings. Fomepizole, a potent alcohol dehydrogenase (ADH) inhibitor, is an efficient and safe antidote that prevents or reduces toxic EG and methanol metabolism. Although no study has compared its efficacy with ethanol, fomepizole is recommended as a first-line antidote. Treatment should be started as soon as possible, based on history and initial findings including anion gap metabolic acidosis, while awaiting measurement of alcohol concentration. Administration is easy (15 mg/kg-loading dose, either intravenously or orally, independent of alcohol concentration, followed by intermittent 10 mg/kg-doses every 12 hours until alcohol concentrations are <30 mg/dl). There is no need to monitor fomepizole concentrations. Administered early, fomepizole prevents EG-related renal failure and methanol-related visual and neurological injuries. When administered prior to the onset of significant acidosis or organ injury, fomepizole may obviate the need for hemodialysis. When dialysis is indicated, 1 mg/kg/h-continuous infusion should be provided to compensate for its elimination. Side-effects are rarely serious and with a lower occurrence than ethanol. Fomepizole is contraindicated in case of allergy to pyrazoles. It is both efficacious and safe in the pediatric population, but is not recommended during pregnancy. In conclusion, fomepizole is an effective and safe first-line antidote for EG and methanol intoxications.
Keywords: ethanol, hemodialysis, metabolic acidosis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Treating nausea and vomiting in palliative care: a review

Glare P, Miller J, Nikolova T, Tickoo R

Clinical Interventions in Aging 2011, 6:243-259

Published Date: 12 September 2011

Comparison of Hanna and Hessburg-Barron trephine and punch systems using histological, anterior segment optical coherence tomography, and elliptical curve fitting models

Moshirfar M, Calvo CM, Kinard KI, Williams LB, Sikder S, Neuffer MC

Clinical Ophthalmology 2011, 5:1121-1125

Published Date: 12 August 2011

Association of an overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis with cytomegalovirus infection

Toyoda-Akui M, Yokomori H, Kaneko F, Shimizu Y, Takeuchi H, Tahara K, Yoshida H, Kondo H, Motoori T, Ohbu M, Oda M, Hibi T

International Journal of General Medicine 2011, 4:397-402

Published Date: 24 May 2011

New and improved strategies for the treatment of gout

Natalie Dubchak, Gerald F Falasca

International Journal of Nephrology and Renovascular Disease 2010, 3:145-166

Published Date: 24 November 2010

Opioid chronopharmacology: influence of timing of infusion on fentanyl’s analgesic efficacy in healthy human volunteers

Merel Boom, Joost Grefkens, Eveline van Dorp, et al

Journal of Pain Research 2010, 3:183-190

Published Date: 21 September 2010

Targeting cancers in the gastrointestinal tract: role of capecitabine

Muhammad Wasif Saif

OncoTargets and Therapy 2009, 2:29-41

Published Date: 25 March 2009

Vascular calcifications as a marker of increased cardiovascular risk: A meta-analysis

R J M W Rennenberg, A G H Kessels, L J Schurgers, J M A van Engelshoven, P W de Leeuw, A A Kroon

Vascular Health and Risk Management 2009, 5:185-197

Published Date: 22 January 2009